MDxHealth S.A. MDXH 深 滬
已收盤 02-06 16:00:00 美东时间
3.53
+0.130
+3.82%
華盛通- 最 高3.59
- 今 開3.56
- 成交量 8.22万股
- 最 低 3.40
- 昨 收 3.40
- 總市值 1.81亿
- 52周最高 5.33
- 市盈率 靜 --
- 換手率 0.16%
- 52周最低 1.35
- 委 比 -8.62%
- 總股本 5136.45万
- 歷史最高 131.70
- 量 比 0.73
- 振 幅 5.59%
- 歷史最低 1.35
- 每 手 1
- 風險率 1.03%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Mdxhealth Advances University Of Oxford Collaboration With GPS Testing In UK ProtecT Trial, Targeting First Genomic Classifier Evidence
Mdxhealth and University of Oxford to validate GPS test in largest randomized trial of treatment effectiveness in patients with localized prostate cancerIRVINE, CA – January XX, 2026 (GlobeNewswire) – Mdxhealth SA
01-06 21:03
Mdxhealth and University of Oxford to validate GPS test in largest randomized trial of treatment effectiveness in patients with localized prostate cancer
Mdxhealth与牛津大学合作启动Genomic Prostate Score (GPS)测试在ProtecT试验中的验证工作。ProtecT试验是全球最大的局部前列腺癌治疗效果随机试验，跟踪1500多名患者20余年，提供长期数据。该研究将评估GPS在主动监测队列中的临床效用，利用ProtecT试验的长期数据进一步验证GPS预测前列腺癌进展和治疗结果的能力。Mdxhealth CEO Michael K. McGarrity称这一合作标志着前列腺癌精准诊断的重要转折点，而牛津大学教授Hamdy则表示，通过整合基因组见解，研究可能重新定义全球医生的风险评估和患者护理方式。
01-06 13:00
美股大行评级 | 潜在涨幅63.56%！拜玛林制药获Truist Securities升目标价至100美元，维持"买入"评级
今日重点评级关注：Truist Securities：维持拜玛林制药"买入"评级，目标价从80美元升至100美元；HC Wainwright & Co.：维持Savara"买入"评级，目标价从8美元升至10美元
2025-12-24 11:17
BTIG Reiterates Buy on MDxHealth, Maintains $7 Price Target
BTIG analyst Mark Massaro reiterates MDxHealth (NASDAQ:MDXH) with a Buy and maintains $7 price target.
2025-12-23 19:52
美股大行评级 | 思科、On Holding、派拓网络等获多家机构上调目标价；Circle 遭富国、德银等多家机构下调目标价
今日重点评级关注：HC Wainwright & Co.：维持PDS Biotechnology"买入"评级，目标价从13美元升至15美元；HC Wainwright & Co.：维持PepGen Inc."买入"评级，目标价从18美元升至20美元
2025-11-14 10:43
BTIG Maintains Buy on MDxHealth, Raises Price Target to $7
BTIG analyst Mark Massaro maintains MDxHealth (NASDAQ:MDXH) with a Buy and raises the price target from $6 to $7.
2025-11-13 18:12
MDxHealth Affirms FY2025 Sales Guidance of $108.000M-$110.000M vs $109.883M Est
MDxHealth (NASDAQ:MDXH) affirms FY2025 sales outlook from $108.000 million-$110.000 million to $108.000 million-$110.000 million vs $109.883 million estimate.
2025-11-13 05:23
MDxHealth Q3 EPS $(0.16) Misses $(0.11) Estimate, Sales $27.433M Miss $28.126M Estimate
MDxHealth (NASDAQ:MDXH) reported quarterly losses of $(0.16) per share which missed the analyst consensus estimate of $(0.11) by 48.15 percent. This is a 60 percent increase over losses of $(0.40) per share from the same
2025-11-13 05:02
Earnings Scheduled For November 12, 2025
Companies Reporting Before The Bell • Hudbay Minerals (NYSE:HBM) is projected t...
2025-11-12 19:11
